This week saw the opening of another multi-centre randomised trial of PSMA PET/CT in Australia. And it's a cracker! PRIMARY 2 follows on from the success of the PRIMARY trial published in European Urology recently (see links below). It is aimed at men with some clinical suspicion of prostate cancer, but no definite lesion on MRI (PIRADS 2/3). Is it ok to just to monitor these men (a la PRECISION)? Many will still undergo prostate biopsy if there is a high clinical suspicion (such as high PSA density, palpable lesion, strong family history), but could PSMA play a role in reducing the number of men undergoing biopsy, and provide a target in some cases? We are joined by trial co-PIs Professor Louise Emmett and Professor Michael Hofman,  Nuclear Medicine Fellow Dr James Buteau and Urology lead A/Professor Daniel Moon, to discuss the innovative trial design. It will recruit 600 men from multiple sites across Australia.  We're excited about this one! Plus a new segment! Urology Registrar Dr Aoife McVey is dropping in to tell us "what caught my eye on twitter" this week. Welcome Aoife!And PROStic nurse consultant Liz Medhurst gives a plug for the upcoming ProsTIC Preceptorship. Regular co-host Dr Renu Eapen is at ASCO GU so Daniel Moon kindly stepped in to help Declan Murphy todayAlso posted on YouTube  Links:PRIMARY trial European Urology 2021 PRIMARY 1 podcastProsTIC PreceptorshipAoife's favourite tweet this week